#fda-approval News & Analysis

5 articles tagged with #fda-approval. AI-curated summaries with sentiment analysis and key takeaways from 50+ sources.

5 articles

GeneralBullishBlockonomi · Jun 276/10

📰

Moderna (MRNA) Stock Soars 13% on In Vivo CAR-T Breakthrough and Flu Vaccine Progress

Moderna's stock jumped 13% following two significant clinical developments: the unveiling of an in vivo CAR-T immunotherapy program targeting autoimmune diseases and a unanimous 9-0 FDA panel vote supporting its mRNA-based flu vaccine candidate. These milestones demonstrate the company's pipeline expansion beyond COVID-19 and validate its mRNA platform's versatility across therapeutic areas.

GeneralBullishBlockonomi · Jun 16/10

📰

Revolution Medicines (RVMD) Stock Soars 20% on Breakthrough Pancreatic Cancer Trial Results

Revolution Medicines' stock surged 20% following positive Phase 3 trial results for daraxonrasib, a pancreatic cancer treatment that doubled survival rates to 13.2 months. The company is proceeding with FDA filing based on the breakthrough data.

AINeutralBlockonomi · May 296/10

🧠

Tempus AI (TEM) Stock Slides Despite FDA Greenlight for Cancer Diagnostic Platform

Tempus AI (TEM) stock declined 1.66% following FDA authorization for its xT CDx tumor-only cancer diagnostic test, a significant milestone in oncology that failed to drive positive market sentiment. The disconnect between regulatory approval and stock performance suggests investor focus may be on profitability, competitive positioning, or broader market conditions rather than product validation alone.

GeneralNeutralFortune Crypto · Jun 214/10

📰

A better sunscreen has been available in Europe for 25 years. It just became legal to sell in the U.S.

Bemotrizinol, an advanced sunscreen ingredient used for 25 years in Europe, Mexico, and Canada, received FDA approval on June 9, marking the first new OTC sunscreen ingredient approved in the United States since 1996. The approval ends a regulatory freeze that significantly lagged behind other developed markets.

GeneralNeutralBlockonomi · Jun 95/10

📰

GSK (GSK) Stock Slides 3% Following $10.6B Nuvalent Acquisition Deal

GSK announced a $10.6 billion acquisition of Nuvalent, a move that triggered a 3% decline in GSK stock. The deal brings two late-stage lung cancer therapeutics into GSK's pipeline, with FDA approval anticipated in 2026, representing the company's continued investment in oncology despite immediate market skepticism.